1
|
Nolin E, Gans S, Llamas L, Bandyopadhyay S, Brittain SM, Bernasconi-Elias P, Carter KP, Loureiro JJ, Thomas JR, Schirle M, Yang Y, Guo N, Roma G, Schuierer S, Beibel M, Lindeman A, Sigoillot F, Chen A, Xie KX, Ho S, Reece-Hoyes J, Weihofen WA, Tyskiewicz K, Hoepfner D, McDonald RI, Guthrie N, Dogra A, Guo H, Shao J, Ding J, Canham SM, Boynton G, George EL, Kang ZB, Antczak C, Porter JA, Wallace O, Tallarico JA, Palmer AE, Jenkins JL, Jain RK, Bushell SM, Fryer CJ. Discovery of a ZIP7 inhibitor from a Notch pathway screen. Nat Chem Biol 2019; 15:179-188. [PMID: 30643281 DOI: 10.1038/s41589-018-0200-7] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 11/14/2018] [Indexed: 12/15/2022]
Abstract
The identification of activating mutations in NOTCH1 in 50% of T cell acute lymphoblastic leukemia has generated interest in elucidating how these mutations contribute to oncogenic transformation and in targeting the pathway. A phenotypic screen identified compounds that interfere with trafficking of Notch and induce apoptosis via an endoplasmic reticulum (ER) stress mechanism. Target identification approaches revealed a role for SLC39A7 (ZIP7), a zinc transport family member, in governing Notch trafficking and signaling. Generation and sequencing of a compound-resistant cell line identified a V430E mutation in ZIP7 that confers transferable resistance to the compound NVS-ZP7-4. NVS-ZP7-4 altered zinc in the ER, and an analog of the compound photoaffinity labeled ZIP7 in cells, suggesting a direct interaction between the compound and ZIP7. NVS-ZP7-4 is the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.
Collapse
Affiliation(s)
- Erin Nolin
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Sara Gans
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Luis Llamas
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | | | | - Kyle P Carter
- Department of Chemistry and Biochemistry and BioFrontiers Institute, University of Colorado, Boulder, CO, USA
| | | | - Jason R Thomas
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Markus Schirle
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Yi Yang
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Ning Guo
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Guglielmo Roma
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Sven Schuierer
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Martin Beibel
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Alicia Lindeman
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Amy Chen
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Kevin X Xie
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Samuel Ho
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | | | | | | | | | | - Abhishek Dogra
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Haibing Guo
- Novartis Institutes for Biomedical Research, Shanghai, China
| | - Jian Shao
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Jian Ding
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Geoff Boynton
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Zhao B Kang
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | | - Owen Wallace
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Amy E Palmer
- Department of Chemistry and Biochemistry and BioFrontiers Institute, University of Colorado, Boulder, CO, USA
| | | | - Rishi K Jain
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Simon M Bushell
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
| | - Christy J Fryer
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
| |
Collapse
|
4
|
McDonald RI, White PB, Weinstein AB, Tam CP, Stahl SS. Enantioselective Pd(II)-catalyzed aerobic oxidative amidation of alkenes and insights into the role of electronic asymmetry in pyridine-oxazoline ligands. Org Lett 2011; 13:2830-3. [PMID: 21534607 PMCID: PMC3103601 DOI: 10.1021/ol200784y] [Citation(s) in RCA: 97] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Enantioselective intramolecular oxidative amidation of alkenes has been achieved using a (pyrox)Pd(II)(TFA)(2) catalyst (pyrox = pyridine-oxazoline, TFA = trifluoroacetate) and O(2) as the sole stoichiometric oxidant. The reactions proceed at room temperature in good-to-excellent yields (58-98%) and with high enantioselectivity (ee = 92-98%). Catalyst-controlled stereoselective cyclization reactions are demonstrated for a number of chiral substrates. DFT calculations suggest that the electronic asymmetry of the pyrox ligand synergizes with steric asymmetry to control the stereochemical outcome of the key amidopalladation step.
Collapse
Affiliation(s)
- Richard I. McDonald
- Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, Wisconsin, 53706
| | - Paul B. White
- Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, Wisconsin, 53706
| | - Adam B. Weinstein
- Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, Wisconsin, 53706
| | - Chun Pong Tam
- Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, Wisconsin, 53706
| | - Shannon S. Stahl
- Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, Wisconsin, 53706
| |
Collapse
|
6
|
McDonald RI, Wong GW, Neupane RP, Stahl SS, Landis CR. Enantioselective hydroformylation of N-vinyl carboxamides, allyl carbamates, and allyl ethers using chiral diazaphospholane ligands. J Am Chem Soc 2011; 132:14027-9. [PMID: 20845958 DOI: 10.1021/ja106674n] [Citation(s) in RCA: 125] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Rhodium complexes of diazaphospholane ligands catalyze the asymmetric hydroformylation of N-vinyl carboxamides, allyl ethers, and allyl carbamates; products include 1,2- and 1,3-aminoaldehydes and 1,3-alkoxyaldehydes. Using glass pressure bottles, short reaction times (generally less than 6 h), and low catalyst loading (commonly 0.5 mol %), 20 substrates are successfully converted to chiral aldehydes with useful regioselectivity and high enantioselectivity (up to 99% ee). Chiral Roche aldehyde is obtained with 97% ee from the hydroformylation of allyl silyl ethers. Commonly difficult substrates such as 1,1- and 1,2-disubstituted alkenes undergo effective hydroformylation with 89-97% ee and complete conversion for six examples. Palladium-catalyzed aerobic oxidative amination of allyl benzyl ether followed by enantioselective hydroformylation yields the β(3)-aminoaldehyde with 74% ee.
Collapse
Affiliation(s)
- Richard I McDonald
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53706, USA
| | | | | | | | | |
Collapse
|
8
|
McDonald RI, Stahl SS. Modular Synthesis of 1,2-Diamine Derivatives via Palladium-Catalyzed Aerobic Oxidative Cyclization of Allylic Sulfamides. Angew Chem Int Ed Engl 2010; 122:5661-5664. [PMID: 21132102 PMCID: PMC2996102 DOI: 10.1002/ange.200906342] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Allylic sulfamides undergo efficient aerobic oxidative cyclization at room temperature, mediated by a new Pd catalyst system consisting of 5% Pd(TFA)(2)/10% DMSO in THF. The synthetic utility of these reactions is enhanced by several features: (1) the sulfamide substrates are accessible in multi-gram scale from the corresponding allylic and primary amines, (2) the cyclic sulfamide products are readily converted to the corresponding 1,2-diamines upon treatment with LiAlH(4), and (3) substrates derived from chiral allylic amines cyclize with very high levels of diastereoselectivity.
Collapse
Affiliation(s)
- Richard I. McDonald
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, WI 53706 (USA), Fax: (+1) 608-262-6143, Homepage: http://www.chem.wisc.edu/~stahl
| | - Shannon S. Stahl
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, WI 53706 (USA), Fax: (+1) 608-262-6143, Homepage: http://www.chem.wisc.edu/~stahl
| |
Collapse
|